PMID- 11584187
OWN - NLM
STAT- MEDLINE
DCOM- 20011204
LR  - 20191105
IS  - 1070-5287 (Print)
IS  - 1070-5287 (Linking)
VI  - 7
IP  - 5
DP  - 2001 Sep
TI  - Orally active heparin and low-molecular-weight heparin.
PG  - 344-8
AB  - The heparins, (unfractionated heparin (UFH) and low-molecular-weight heparins 
      (LMWH)) given by subcutaneous or intravenous injection have been used extensively 
      in the prevention and treatment of both venous and arterial thromboembolic 
      disorders. The increasing use of the heparins, LMWHs in particular, in the out of 
      hospital setting has stimulated interest in the development of orally absorbable 
      antithrombotic agents that require little or no monitoring, and this includes the 
      heparins. UFH or LMWH delivered orally has been shown to have an antithrombotic 
      effect in animal thrombosis models although there is little change in plasma 
      coagulation tests. The addition of a simple organic chemical N 
      -(8-(2-hydroxybenzoyl)amino)caprylate (SNAC) to UFH markedly enhances its 
      absorption. A phase II study in patients undergoing total hip replacement 
      indicated that SNAC heparin in two different doses was as effective and safe as 
      UFH given subcutaneously. A phase III clinical trial comparing two doses of SNAC 
      heparin given orally with LMWH by subcutaneous injection for the prevention of 
      venous thromboembolism in patients undergoing total hip replacement is currently 
      underway.
FAU - Pineo, G F
AU  - Pineo GF
AD  - Thrombosis Research Unit, Foothills Hospital, University of Calgary, 1403 29th 
      Street NW, Calgary, Alberta T2N 2T9, Canada. pineo@ucalgary.ca
FAU - Hull, R D
AU  - Hull RD
FAU - Marder, V J
AU  - Marder VJ
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Pulm Med
JT  - Current opinion in pulmonary medicine
JID - 9503765
RN  - 0 (Anticoagulants)
RN  - 0 (Caprylates)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (N-(8-(2-hydroxybenzoyl)amino)caprylate)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Anticoagulants/administration & dosage/*therapeutic use
MH  - Arthroplasty, Replacement, Hip/adverse effects
MH  - Caprylates/pharmacology/therapeutic use
MH  - Disease Models, Animal
MH  - Drug Delivery Systems
MH  - Heparin/administration & dosage/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/administration & dosage/*therapeutic use
MH  - Humans
MH  - Intestinal Absorption
MH  - Meta-Analysis as Topic
MH  - Thromboembolism/etiology/*prevention & control
RF  - 31
EDAT- 2001/10/05 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/10/05 10:00
PHST- 2001/10/05 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/10/05 10:00 [entrez]
AID - 10.1097/00063198-200109000-00016 [doi]
PST - ppublish
SO  - Curr Opin Pulm Med. 2001 Sep;7(5):344-8. doi: 10.1097/00063198-200109000-00016.